- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
- Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
- Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
- Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
More ▼
Key statistics
On Tuesday, Contineum Therapeutics Inc (CTNM:NSQ) closed at 20.69, -5.95% below its 52-week high of 22.00, set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.65 |
---|---|
High | 21.37 |
Low | 20.49 |
Bid | 17.50 |
Offer | 32.89 |
Previous close | 20.69 |
Average volume | 261.41k |
---|---|
Shares outstanding | 25.72m |
Free float | 16.87m |
P/E (TTM) | 27.18 |
Market cap | 532.21m USD |
EPS (TTM) | 0.7611 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼